NUVL Stock - Nuvalent, Inc.
Unlock GoAI Insights for NUVL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-280,368,000 | $-149,492,000 | $-86,108,000 | $-45,817,000 | $-16,905,000 |
| Net Income | $-260,756,000 | $-126,219,000 | $-81,854,000 | $-46,338,000 | $-14,556,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.93 | $-2.17 | $-1.65 | $-2.13 | $-0.64 |
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteEarnings History & Surprises
NUVLEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | $-1.48 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-1.39 | $-1.70 | -22.3% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-1.27 | $-1.31 | -3.1% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-1.14 | $-1.18 | -3.5% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-1.04 | $-1.05 | -1.0% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.93 | $-1.28 | -37.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.76 | $-0.88 | -15.8% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.67 | $-0.69 | -3.0% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $-0.59 | $-0.62 | -5.1% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.59 | $-0.59 | 0.0% | = MET |
Q3 2023 | Aug 10, 2023 | $-0.53 | $-0.51 | +3.8% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.51 | $-0.44 | +13.7% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.43 | $-0.49 | -14.0% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.46 | $-0.41 | +10.9% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.43 | $-0.38 | +11.6% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.40 | $-0.36 | +10.0% | ✓ BEAT |
Q1 2022 | Mar 29, 2022 | $-0.32 | $-0.36 | -12.5% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.25 | $-0.39 | -56.0% | ✗ MISS |
Q3 2021 | Sep 8, 2021 | $-0.19 | $-3.17 | -1568.4% | ✗ MISS |
Q3 2021 | Jul 30, 2021 | — | $-0.30 | — | — |
Latest News
Frequently Asked Questions about NUVL
What is NUVL's current stock price?
What is the analyst price target for NUVL?
What sector is Nuvalent, Inc. in?
What is NUVL's market cap?
Does NUVL pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NUVL for comparison